Corvus Pharmaceuticals Inc CRVS
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $10.41
- Day Range
- $9.82–10.31
- 52-Week Range
- $6.39–26.95
- Bid/Ask
- $10.00 / $10.42
- Shares Outstanding
- 84.12M
- Market Cap
- $858.87M
- Volume/Avg
- 359 / 1M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Corvus Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. It believes its proprietary product candidates have broad potential to address immune mediated diseases, inflammatory diseases and cancers. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The company operates in one primary business activity and operate as one reportable segment.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 37
- Website
- https://www.corvuspharma.com
Valuation
|
Metric
|
CRVS
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 3.81 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
CRVS
Financial Strength
|
Metric
|
CRVS
|
|---|---|
Quick Ratio | 15.88 |
Current Ratio | 16.16 |
Interest Coverage | — |
Quick Ratio
CRVS
Profitability
|
Metric
|
CRVS
|
|---|---|
Return on Assets (Normalized) | −31.39% |
Return on Equity (Normalized) | −33.90% |
Return on Invested Capital (Normalized) | −37.45% |
Return on Assets
CRVS
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|#GbKTl@ | LOCK|>fw? | $128B | |||
| Moderna Inc
MRNA
| LOCK|z@G^pG | LOCK|F% | $79B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|%>N>&v | LOCK|@$ff | $76B | |||
| argenx SE ADR
ARGX
| LOCK|X>mPbz? | LOCK|?# | $50B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|!f@@krl | LOCK|?nw | $41B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|TH%XNq | LOCK|%SWSj | $30B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|fDk@^%&s | LOCK|Bwr@ | $25B | |||
| BioNTech SE ADR
BNTX
| LOCK|!h?Bk# | LOCK|#q | $23B | |||
| Incyte Corp
INCY
| LOCK|qR$KgJF | LOCK|pk | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|kw?Rc< | LOCK|ZXy | $14B |
United States